Proyectos ERA Permed Navarra - Medicinapersonalizada
ERA PerMed projects in Navarre
The ERANet PerMed promotes joint transnational calls for innovative research projects in Personalized Medicine.
Backed by 32 partners from 23 countries and co-financed by the European Commission, including the Government of Navarra (Department of Industry, Energy and Strategic Projects of the S4).
1. Align national research strategies around Personalized Medicine.
2. Promote excellence.
3. Strengthen the competitiveness of European actors in Personalized Medicine.
4. Improve European collaboration with non-EU countries.
European Call PerMed 2022:
The call has two phases: (you're still on time!!!)
Phase I: Presentation of Pre-proposals: December 1, 2021 to February 17, 2022.
Phase II: Submission of Proposals: June 14, 2022
Proposals that pass Phase I are called to submit to Phase II.
Those Navarrese proposals that pass the European Phase II, are called to a Regional Call in order to be subsidized by the Government of Navarre.
Navarra has opted for the strategic sector of Personalized Medicine and has allocated 1 million euros for this 2022 call.
Latest Navarran Projects Subsidized by the Government of Navarra in the highly competitive PerMed Call:
MEET-AML. Metabolic vulnerabilities for personalized therapeutic approaches in acute myeloid leukemia
Less tan 30% of acute myeloid leukemia (AML) patients survive longer than 5 years. The metabolism of leukemic cells supports their production of energy and building blocks for growth and their capacity to resist to external attacks, as therapies. The study aims to identify metabolic activities of leukemic cells that lead to tumor cell death, once they have been switched off. This approach will combine genome and metabolism analysis, in order to identify and test, in the laboratory, personalized therapies. Moreover, the study will capture AML patients´ preferences towards benefits and risks associated with different treatment options as well as their perspective towards this personalized approach. The study results will converge to a new model of approaching the patient and taking decisions on his/her therapeutic path, based on his/her specificities, as patient and as human being on direct patient involvement.
RESPECT - Renal MRI standardisation to improve personalized management of CKD patients.
Chronic Kidney Disease (CKD) represents a global and increasing health burden with high economic cost. CKD patients exhibit a progressive disease, nonetheless a failure of current therapies has been demonstrated and an alarming number of clinical trials have failded. Better methods are urgently needed for earlier diagnosis and improved patient stratification, targeted treatment, and monitoring. Renal multiparametric Magnetic Resonance Imaging (MRI) has emerged as a promising non-invasive technique for characterisation of renal physiology and pathophysiology. However, current methodological differences across studies hinder reliable comparisons, and additional evidence for clinical validity and utility of renal MRI is required. RESPECT addresses the unmet needs with a multinational, multidisciplinary and intersectoral project that will set up and technically validate a scalable standardised renal MRI infrastructure, allowing multicentre clinical research. The project will also set up an open-access platform for renal MRI data sharing and processing, taking advantage of latest artificial intelligence developments, and will develop MRI data sharing guidelines taking patient, healthcare and ethic professionals´ perspective into account. The project will finally provide preliminary cross-institutional evidence of renal MRI feasibility and utility in characterising and staging CKD. This is fundamental for renal MRI ultimate transfer to clinical practice for personalized medicine.
European Projects Subsidized by PerMed
Newsletter with all the PerMed Europe Projects (there is a wide variety)
Other ERA PerMed projects with navarrese participation:
EV-glio project Plasma extracellular vesicles (EVs): the key for precision medicine in Glioblastoma. With Jaime Gallego Pérez de Larraya as partner/collaborator. Know more